The European Medicines Agency (EMA) gave initial endorsement to a new approach methodology that replaces live animal controls in early toxicity testing with “virtual counterparts” derived from historical animal control databases. The endorsement is framed as a step toward data that may eventually support marketing-approval applications. The EMA’s decision comes as regulators continue pushing the modernization of preclinical safety programs using NAMs, including computational and virtual control strategies. While the scope is limited, it is the first formal endorsement of this specific direction. For biotech sponsors and CROs, the development is material for study design planning—especially where early toxicity packages must be assembled under timelines constrained by both scientific uncertainty and animal-use governance.